(Q22241650)

English

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

Europe PubMed Central

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

multiple sclerosis

0 references

Janis M. Miyasaki

2

object named as

Janis M Miyasaki

author given names

Janis M

author last names

Miyasaki

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

5

object named as

Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

James J Marriott

1

author given names

James J

author last names

Marriott

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Gary Gronseth

3

author given names

Gary

author last names

Gronseth

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Paul W O'Connor

4

author given names

Paul W

author last names

O'Connor

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

0 references

publication date

1 May 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

74

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1463-1470

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

19 March 2017

Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

12 September 2017

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

12 September 2017

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

12 September 2017

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

12 September 2017

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

12 September 2017

Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

30 May 2018

Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

30 May 2018

Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Therapy-related leukemia in mitozantrone treated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Therapy-related acute promyelocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871006

29 November 2018

Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20439849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitoxantrone treatment of multiple sclerosis: safety considerations

1 reference

https://pubmed.ncbi.nlm.nih.gov/20439849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20439849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20439849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secondary leukemias induced by topoisomerase-targeted drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/20439849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1212/WNL.0B013E3181DC1AE0

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439849%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q22241650&oldid=1982205048"